Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
Yoga Effect on Quality of Life Study Among Patients With Idiopathic Pulmonary Fibrosis
This study will evaluate whether regular yoga exercises designed specifically for patients with Idiopathic Pulmonary Fibrosis is associated with any change in quality of life. Half of the participants will be randomized to yoga, half to usual care. After the first group completes 12 weeks of yoga, the patients who were randomized to usual care will completed 12 weeks of yoga.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic (scarring) disease of
the lung of unknown cause. Approximately 100,000 Americans will die from IPF this year.
There is no cure for IPF other than lung transplantation, which only 1% of patients will
receive. Recently, 2 drugs were approved by the FDA to slow the rate of decline in lung
function among patients with IPF. These drugs do not decrease symptoms or improve quality of
life.
Symptoms of IPF include shortness of breath, cough, and fatigue, all of which may also
adversely affect quality of life. Yoga is a practice of exercises, including breathing
exercises, that has been shown to be relatively safe and to improve quality of life in some
patients with other advanced lung diseases. We hypothesize that regular yoga and breathing
exercises, specifically designed for patients with Idiopathic Pulmonary Fibrosis, over a
period of 12 weeks will lead to improved quality of life as measured by several different
quality of life questionnaires.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
| Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
| Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
| Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
| Active, not recruiting |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
| Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
| Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
| Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
| Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
| Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
| Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00532233 -
SD, IL-13 Production Rate in IPF
|
Phase 2 | |
| Completed |
NCT00540475 -
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
|